If after seeing Amarin (AMRN) stock tumble 35% over the past year, you consoled yourself with the knowledge that “at least it can’t get any worse” — surprise! It just got worse.On Monday, a judge for the United States District Court for the District of Nevada ruled against Amarin and in favor of two generic drug manufacturers seeking to produce drugs based on Amarin’s Vascepa hypertriglyceridemia treatment, invalidating six Amarin patents in the process. Of course, Amarin quickly promised to “vigorously pursue all available remedies, including an appeal of the Court’s decision and a preliminary injunction pending appeal to … …read more
Source:: Yahoo Finance
